Conway, Alicia-Marie http://orcid.org/0000-0003-2635-8206
Pearce, Simon P. http://orcid.org/0000-0002-1680-5538
Clipson, Alexandra http://orcid.org/0000-0002-4568-4173
Hill, Steven M. http://orcid.org/0000-0002-5909-692X
Chemi, Francesca
Slane-Tan, Dan
Ferdous, Saba
Hossain, A. S. Md Mukarram http://orcid.org/0000-0003-2654-8982
Kamieniecka, Katarzyna
White, Daniel J.
Mitchell, Claire
Kerr, Alastair http://orcid.org/0000-0001-9207-6050
Krebs, Matthew G.
Brady, Gerard
Dive, Caroline http://orcid.org/0000-0002-1726-8850
Cook, Natalie http://orcid.org/0000-0003-2606-1082
Rothwell, Dominic G. http://orcid.org/0000-0002-8757-3893
Funding for this research was provided by:
Cancer Research UK (C5759/A27412, A25254, A20465)
Article History
Received: 12 October 2023
Accepted: 18 March 2024
First Online: 17 April 2024
Competing interests
: C.D. receives research grants/support from AstraZeneca, Astex Pharmaceuticals, Bioven, Amgen, Carrick Therapeutics, Merck AG, Taiho Oncology, GSK, Bayer, Boehringer Ingelheim, Roche, BMS, Novartis, Celgene, Epigene Therapeutics Inc, Angle PLC, Menarini, Clearbridge Biomedics, Thermo Fisher Scientific, Neomed Therapeutics. C.D. has received/receives honoraria/consultancy fees from Biocartis, Merck, AstraZeneca and GRAIL. Outside of the scope of work, research funding/educational research grants has been received from by the Experimental Cancer Medicine Team (PI: Cook) from AstraZeneca, Bayer, Pfizer, Orion, Taiho, Oncology, Roche, Starpharma, Eisai, RedX, UCB, Boeringher, Merck, Stemline Tarveda and Avacta. M.G.K has received consultancy/advisory board fees from Bayer, Guaradant Health, Janssen, Roche, Seattle Genetics; speakers fees from Janssen, Roche; research funding from Novartis, Roche and travel expenses from Immutep, Janseen and Roche. The remaining authors declare no competing interests.